Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Arcus Biosciences (RCUS) over the last 9 years, with Sep 2025 value amounting to $14.0 million.

  • Arcus Biosciences' Share-based Compensation fell 26.32% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year decrease of 19.48%. This contributed to the annual value of $76.0 million for FY2024, which is 4.11% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Share-based Compensation is $14.0 million, which was down 6.67% from $15.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Share-based Compensation high stood at $20.0 million for Q1 2024, and its period low was $12.8 million during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $18.0 million (2023), whereas its average is $17.6 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 268.60% in 2021, then declined by 26.32% in 2025.
  • Over the past 5 years, Arcus Biosciences' Share-based Compensation (Quarterly) stood at $14.3 million in 2021, then grew by 18.99% to $17.0 million in 2022, then climbed by 5.88% to $18.0 million in 2023, then dropped by 5.56% to $17.0 million in 2024, then dropped by 26.32% to $14.0 million in 2025.
  • Its Share-based Compensation was $14.0 million in Q3 2025, compared to $15.0 million in Q2 2025 and $16.0 million in Q1 2025.